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Abstract 
 
This thesis describes work carried out on the synthesis of novel 5- and 11-substituted 
ellipticines and derivatives of the ellipticine analogues, isoellipticine and deazaellipticine, 
followed by investigation of their potential as anti-cancer agents. 
 
Preparation of the key 5- and 11-substituted ellipticine targets involved the development of 
regiospecific, sequential alkylation reactions with alkenyllithium and Grignard reagents. 
Investigation of these novel reactions resulted in a new route towards 5-substituted ellipticines 
via Grignard reaction with vinylmagnesium bromide. These novel 5-vinylellipticine derivatives 
were further functionalised in an ozonolysis reaction, followed by oxidation to give a range of 
novel 5-substituted ellipticines. Less success was encountered in the 11-substituted ellipticine 
series, however preparation of these derivatives using a previously published route was 
accomplished, and the resulting 11-formylellipticine was further derivatised to give a panel of 
novel 9- and 11-substituted ellipticines, incorporating amide, carboxylate, imine and amine 
functionality. 
 
The successful route towards 5-substituted ellipticines was applied to the preparation of a 
range of novel 11-substituted isoellipticines and 6-substituted deazaellipticines, the first time 
substantial synthesis has been undertaken with these analogues. In addition to this, the first 
preparation of isoellipticinium salts is described, and a panel of novel isoellipticinium, 
7-formylisoellipticinium and 7-hydroxyisoellipticinium salts were synthesised in good yields. 
 
Biological evaluation of a panel of 43 novel ellipticine, isoellipticine and deazaellipticine 
derivatives was accomplished with a topoisomerase II decatenation assay and submission to 
the NCI 60-cell line screen. Four novel isoellipticine topoisomerase II inhibitors were 
identified from the decatenation assay, with strong activity at 10 µM. In addition to this, NCI 
screening identified five highly cytotoxic ellipticine and isoellipticine compounds with 
remarkable selectivity profiles for different cancer types. These novel lead compounds 
represent new templates for further research and synthesis. 
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1.1 Cancer 
 
Cancer may be defined as a set of diseases characterised by unregulated cell growth leading to 
invasion of surrounding tissues and spread (metastasis) to other parts of the body.1 Although 
known to the early Egyptians, advances in modern medicine and the subsequent increase in 
life expectancy have resulted in cancer becoming one of the leading causes of death today. In 
2008, the World Health Organisation found that 13.3% of deaths worldwide were caused by 
malignant neoplasms, second only to cardiovascular disease at 30.5%.2  
 
The core feature of cancer is uncontrolled cell proliferation, however this does not necessarily 
mean faster proliferation. While some cancers do proliferate faster than normal cells, others, 
such as breast cancer, proliferate slowly. Other key features of cancer cells are extended life 
and a higher degree of autonomy compared to normal cells. The most common terminology 
used in relation to cancer are the terms benign and malignant - a benign tumour is 
characterised by increased cell mass, with clearly defined boundaries and is generally easily 
treated. On the other hand, a malignant neoplasm or tumour is defined by invasion of 
surrounding tissues and metastasis to remote tissue. Specific cancers are described by their cell 
of origin and the tissue in which they arise (Table 1.1).1 
 
Epithelium – carcinoma 
Glandular e.g. prostate: adenocarcinoma 
Squamous e.g. cervix: carcinoma 
Mesenchyme – sarcoma  
Smooth muscle Leiomyosarcoma 
Bone Osteosarcoma 
Nervous system 
Eye Retinoblastoma 
Astrocytes Astrocytoma 
White blood cells – leukaemia 
(chronic or acute) 
Myeloid cells Myelocytic leukaemia 
Lymphocytes Lymphocytic leukaemia 
Lymphoma Solid tumour derived from B or T lymphocytes 
Table 1.1: Classification of common cancer types1 
Carcinogenesis, the multi-step process by which a cancer is formed, involves accumulation of 
sucessive mutations in oncogenes and suppressor genes that deregulate the cell cycle, e.g. 
point mutations, translocation, deletion and amplification.3 Once a cancer is formed, such 
changes can continue to accumulate due to deregulation of cell processes, often leading to 
increased difficulty in treatment. 
 
It is difficult to identify exact causes for specific cancers, however definitive environmental 
and genetic risk factors can be identified, e.g. smoking is a major risk factor for lung cancer. 
Diet, increasing age and family history of cancer have all been identified as risk factors which 
increase the chance of developing cancer. In addition to this, cancers have different incidences 
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in different populations e.g. high rates of stomach cancers in Japan, melanomas in Australia 
and liver cancers in China. 
  
The treatment of cancer is based on the removal or killing (or both) of cancer cells whilst 
minimising unwanted side effects. This may be achieved by surgery, radiotherapy or 
chemotherapy, alone or more commonly, in combination. The majority of chemotherapeutic 
agents act by preventing mitosis or DNA synthesis. Anticancer drugs can be classified 
according to their mechanism of action, such as DNA-interactive agents, antimetabolites, anti-
tubulin agents, molecular targeting agents, hormones, monoclonal antibodies and other 
biological agents. Some of the most common anticancer drugs are summarised by mechanism 
of action in Table 1.2 (information collected from several sources).1,4,5  
 
DNA Interacting Agents  
Alkylating agents Alkylation of DNA bases in either the minor or major grooves 
- dacarbazine, procarbazine and temozolomide 
Cross-linking agents Binding to DNA resulting in intra-strand or inter-strand cross-linking 
- Platinum complexes e.g. cisplatin, carboplatin, oxaliplatin 
- Nitrogen mustards e.g., cyclophosphamide, ifosfamide 
Intercalating agents Binding between base pairs 
- Anthracyclines e.g. doxorubicin, epirubicin 
- Mitoxantrone and actinomycin-D. 
Topoisomerase Inhibitors - Topoisomerase I: camptothecins  
- Topoisomerase II: anthracyclines, etoposide 
DNA cleaving agents Cause strand scission at the binding site. 
- Bleomycin 
Antimetabolites  
Pyrimidine analogues 5-Fluorouracil 
Purine analogues Mercaptopurine 
Inhibitors Methotrexate: inhibits DHF reductase 
Antitublin Agents  
Taxols Docetaxel, paclitaxel  
Vinca alkaloids Vinblastine, vincristine, vinorelbine 
Tyrosine Kinase Inhibitors  
Small molecule - Imatinib (Gleevec): inhibits ABL, c-Kit kinase, PDGFR 
- Gefitinib (Iressa): inhibits EGFR 
Monoclonal antibody Trastuzumab: inhibits EGFR2, HER2, neu 
Angiogenesis/Metastasis Inhibitors 
Monoclonal antibody Bevacizumab (Avastin): targets VEGF 
Table 1.2: Common anticancer drugs and their mechanisms of action1,4,5 
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The development and effectiveness of chemotherapeutic treatments is generally hampered by 
the high toxicity of most anticancer drugs and the non-selectivity of their action. This has lead 
to a continual search for new anticancer agents, especially amongst the vast array of natural 
products. 
 
 
1.2 Ellipticine 
 
The natural product ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) 1 was first isolated 
from the leaf material of Ochrosia elliptica Labill by Goodwin et al. in 1959.6 This small tropical 
evergreen tree belonging to the Apocynaceae family also contained several other alkaloids, 
including 9-methoxyellipticine. Ellipticine has since been isolated from several other plants of 
the Apocynaceae family (Ochrosia vieillardii, Ochrosia acuminate and Ochrosia moorei)7–9 and from 
Strychnos dinkagei of the Loganiaceae family.10,11 
 
 
 
 
 
Figure 1.1: Ellipticine 1 
Ellipticine and its derivatives were found to exhibit potent anticancer activity and have been 
subject to much study over the last fifty years. Woodward et al. reported the first synthesis of 
ellipticine in 1959 and a vast array of synthetic strategies has been published since (these are 
discussed in chapter 2).12 Parallel to this, research into the biological activity of ellipticine, in 
particular its interaction with DNA, has elucidated much of its mechanism of action.  
 
 Reviews  1.2.1
The most extensive reviews of the biological activity of ellipticine are those of Christian 
Auclair (1987) and Garbett & Graves (2004).13,14 Harding and Grummitt also published a 
mini-review of 9-hydroxyellipticine and its derivatives in 2003.15 The main mechanisms 
discussed in these reviews are intercalation with DNA, topoisomerase II inhibition and bio-
oxidation, however recent research has highlighted some significant new mechanisms of 
action. 
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1.3 Mechanisms of Action 
 
The mechanisms of action of ellipticine are considered here in three sections: interaction with 
DNA, kinase inhibition and other mechanisms. Of these, interactions with DNA are well 
established, and include intercalation, topoisomerase II inhibition, bio-oxidation and adduct 
formation. Inhibition of c-Kit kinase and AKT have been reported in the last five to six years 
and open up the vast area of kinase inhibition for investigation. Finally, one of the most 
interesting developments in the area is the rescue of mutant p53 function by ellipticine, which 
has come to light in the last decade.  
 
 Interaction with DNA 1.3.1
Ellipticine has been shown to interact with DNA in several ways, including non-covalent 
interactions such as intercalation and topoisomerase II inhibition, along with covalent adduct 
formation via bio-oxidation. 
 
1.3.1.1 Intercalation  
Intercalation occurs when a planar aromatic or heteroaromatic ring system inserts between 
base pairs of DNA and distorts its structure. Once bound, the drug can inhibit enzymes 
involved in replication and transcription processes, e.g. topoisomerase II. Intercalation was 
first described in 1961 by Lerman16 for the synthetic acridine dye proflavine, used in world 
war II to dress wounds due to it’s powerful antiseptic properties. It is now understood to be 
the major DNA binding mode of any planar polyaromatic ligand. 
 
Generally, a planar intercalating drug is held by stacking (van der Waals) interactions with the 
base pairs of DNA above and below (Figure 1.2). In addition to this, some intercalating drugs 
also contain cationic groups, which can interact with the phosphate group of the backbone.17  
 
 
 
 
 
 
       Guanine – Cytosine 
 
 
 
 
 
       Adenine – Thymine 
Figure 1.2: DNA base pairs (purines in blue and pyrimidines in green) and intercalation model 
Intercalator	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When a drug intercalates with DNA, the base pair separation at that site is immediately 
increased from its normal value of 3.3 Å and the overall winding angle of the DNA double 
helix is altered, usually referred to as the unwinding angle.  
 
In 1975, Kohn et al. measured the UV absorption spectrum of ellipticine in the presence of 
calf-thymus DNA.18 The spectrum exhibited hypochromic and bathochromic changes 
indicating that ellipticine was binding to DNA via intercalation. An unwinding angle of 7.9º 
was reported, however, this was based on a value of 12º for ethidium, which was later found 
to be much higher (26º). 
Four years later, Jain et al. obtained an x-ray crystal structure of ellipticine complexed with a 
self-complementary dinucleoside monophosphate.19 Ellipticine intercalated parallel to the base 
pairs of the CpG – GpC dinucleoside with 6.7 Å separation between the pairs and an 
unwinding angle of 10 – 12 º. While the crystal data was useful, it was questionable whether a 
simple dinucleoside could be representative of the real DNA binding mode. 
Dodin et al. re-estimated the pKa of ellipticine at 7.4 and carried out similar studies to Kohn18 
but at pH 5 and pH 9.20 The ellipticinium cation bound slightly stronger to calf – thymus 
DNA than ellipticine, with affinity constants of 8.3 × 105 M-1 and 3.3 × 105 M-1 at pH 5 & 9 
respectively. The group also used fluorescence spectroscopy in deuterated buffer to study 
interactions of N-methylellipticinium 2 and 9-hydroxy-N-methylellipticinium 3 with DNA 
(Figure 1.3). N-Methylellipticinium 2 showed no preference for intercalation sites, while 3 was 
found to interact with a site containing at least one G-C base pair, inferring that the 9-hydroxy 
group confers G-C preference. 
 
 
2  R=H 
3  R=OH 
 
Figure 1.3 
Monnot et al. utilised UV absorption and circular dichroism (CD) experiments to study 9-
hydroxy-1-methylellipticine 4 and 1,2-dimethyl-7-hydroxyisoellipticinium 5 (Figure 1.4) with 
poly d(A-T).poly d(A-T) as a DNA model.21  
 
 
 
 
 
    4      5 
Figure 1.4 
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Circular dichroism (CD) is the difference in absorbance of left and right circularly polarized 
light. The ellipticines lack chirality, but optical activity can be conferred by intercalation in the 
asymmetric environment of DNA, while unbound molecules remain optically silent. Thus, 
CD can help distinguish between free molecules in solution and those bound to DNA. At a 
low drug – DNA ratio 9-hydroxy-1-methylellipticine 4 showed an intercalatory binding mode 
(Figure 1.5, mode A), while at high drug – DNA ratio an outside binding mode was also 
observed (mode B). In contrast, only one binding mode was seen for 1,2-dimethyl-7-
hydroxyisoellipticinium 5, self-stacked molecules interacted at the surface of DNA in an 
outside binding mode (mode C). 
 
 
   A          B         C 
Figure 1.5: Binding modes of Ellipticine derivatives (adapted from Monnot et al.)21 
Similar results were reported by Dodin et al. from their temperature – jump experiments with 
ellipticine and several derivatives.22 While ellipticine itself only exhibited intercalation, 
derivatives such as N-methylellipticinium 2 and 9-hydroxy-N-methylellipticinium 3 (Figure 
1.3) showed both intercalation and outside binding modes.  
 
In 1996, Elcock et al. published molecular dynamics simulations investigating intercalation of 
9-hydroxyellipticine 6 (Figure 1.6) with the DNA oligonucleotide d(ATATATATATAT)2.
23 
Four simulations were carried out, with different initial orientations of the drug. All the 
simulations converged in placing the pyridine ring in the minor groove, however only two of 
the four converged overall on the same binding site. In contrast to previous publications, it 
was concluded that a perpendicular orientation of 9-hydroxyellipticine to the axis of the base 
pairs was most likely. However, the same group later published CD calculations suggesting 
that intercalation of 9-hydroxyellipticine 6 occurs with the 9-hydroxy group in the minor 
groove and the pyridine ring in the major groove (i.e. still perpendicular to base pairs but 
opposite direction).24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HN
N
H
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N
H
HO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 | Biological Introduction 
10 
intercalate in an orientation perpendicular to the long base-pair axis.
As every derivative may have a different binding mode, extensive and
accurate information on how the drugs of this family interact with
DNA is needed in order to understand their mechanism of action.
Here, we report the crystal structure determination of ellipticine in
complex with a 6 bp DNA at 1.5 A˚ resolution, compare it with the
previous crystallographic study of the same drug within a 2 bp
structure and discuss the effect of ellipticine intercalation on DNA
unwinding and lengthening.
2. Materials and methods
2.1. Crystallization and data collection
Crystallization conditions were screened using the Nucleic Acid
Mini Screen (Berger et al., 1996). Yellow hexagonal crystals were
grown at 293 K by the hanging-drop vapour-diffusion technique by
mixing 2.0 ml 5 mM ellipticine, 1.0 ml 1.5 mM d(CGATCG)2 and 1.0 ml
crystallization solution (12%MPD, 40 mM sodium cacodylate pH 5.5,
20 mM cobalt hexammine, 12 mM sodium chloride and 80 mM
potassium chloride) equilibrated against 500 ml 78% MPD. Both low-
and high-resolution data sets were collected on a 130 mmMAR CCD
detector (MAR Research) from a single crystal kept at 120 K using
synchrotron radiation (! = 0.976 A˚) at the ESRF (Grenoble)
microfocus beamline ID13. Data were indexed, integrated and scaled
with theXDS package (Kabsch, 1993), yielding an Rmerge of 8.7% and
a completeness of 99.6% in the resolution range 16.7–1.5 A˚. Data-
collection statistics are shown in Table 1.
2.2. Structure solution and refinement
The structure was solved by molecular replacement with AMoRe
(Navaza, 1994) using the DNA coordinates of the d(CGTACG)–
D232 structure (Shui et al., 2000; NDB code DD0018) as a starting
model. Reflections within the resolution range 16.7–3.0 A˚ were used
for rotation- and translation-function calculations. One clear solution
was found with a correlation coefficient of 54.8% and a crystallo-
graphic R factor of 46.8% (values for the second highest peak are 46.0
and 49.6%, respectively). Refinement followed with REFMAC5
(Murshudov et al., 1999). The optimum orientation of the intercalated
ellipticine was identified by placing the drug in each of the four
possible positions and refining until the best fit and corresponding
best R factor and Rfree were found. At this stage, an iterative
refinement procedure was carried out using REFMAC5 with ARP/
wARP (Perrakis et al., 1999), interspersed with inspection of electron-
density maps, water positioning and manual model rebuilding with
TURBO-FRODO (Roussel & Cambillau, 1989). All data were used
(16.7–1.5 A˚) with no low-resolution or " cutoff. A randomly selected
221 reflections (5%) were set aside for Rfree calculations. The final
refinement statistics are shown in Table 1. The helical parameters of
the DNA were analyzed with the program CURVES (Lavery &
Sklenar, 1988).
short communications
1010 Canals et al. ! Ellipticine Acta Cryst. (2005). D61, 1009–1012
Figure 2
Stereoviews of the ellipticine–DNA complex. (a) The bis-intercalated
d(CGATCG)2 hexanucleotide forming an asymmetric unit. The drug and each
strand of the DNA are represented in different colours. Red spheres represent Co
atoms. (b) 2Fo " Fc electron-density map at the area of the intercalated ligand,
looking into the minor groove. The map was contoured at the 1.0" level. (c)
Projection down the helix axis of a d(CpG)-d(GpC) dinucleotide with the
sandwiched ligand. (d) Superimposition of the structure from Jain et al. (1979) in
yellow and the equivalent part of the present structure in blue. (e) Three
asymmetric units illustrating the crystal packing of the ellipticine–d(CGATCG)2
structure. The drug is always coloured green and symmetry neighbours are in a
different colour. Water molecules (spheres) are included.
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crystallization solution (12%MPD, 40 mM sodium cacodylate pH 5.5,
20 mM cobalt hexammine, 12 mM sodium chloride and 80 mM
potassium chloride) equilibrated against 500 ml 78% MPD. Both low-
and high-resolution data sets were collected on a 130 mmMAR CCD
detector (MAR Research) from a single crystal kept at 120 K using
synchrotron radiation (! = 0.976 A˚) at the ESRF (Grenoble)
microfocus beamline ID13. Data were indexed, integrated and scaled
with theXDS package (Kabsch, 1993), yielding an Rmerge of 8.7% and
a compl teness f 99.6% in the resolution range 16.7–1.5 A˚. Data-
collection statistics are shown in Table 1.
2.2. Structure solution and refinement
The structure was solved by molecular replacement with AMoRe
(Navaza, 1994) using the DNA coordinates of the d(CGTACG)–
D232 structure (Shui et al., 2000; NDB code DD0018) as a starting
model. Reflections within the resolution range 16.7–3.0 A˚ were used
for rotation- and translation-function calculations. One clear solution
was found with a correlation coefficient of 54.8% and a crystallo-
graphic R factor of 46.8% (values for the second highest peak are 46.0
and 49.6%, respec ively). Refinement followed with REFMAC5
(Murshudov et al., 1999). The optimum orientation of the intercalated
ellipticine was identified by placing the drug in each of the four
possible positions and refining until the best fit and corresponding
best R factor and Rfree were found. At this stage, an iterative
refinement procedure was carried out using REFMAC5 with ARP/
wARP (Perrakis et al., 1999), interspersed with inspection of electron-
density maps, water positioning and manual model rebuilding with
TURBO-FRODO (Roussel & Cambillau, 1989). All data were used
(16.7–1.5 A˚) with no low-resolution or " cutoff. A randomly selected
221 reflections (5%) were set aside for Rfree calculations. The final
refinement statistics are shown in Table 1. The helical parameters of
the DNA were analyzed with the program CURVES (Lavery &
Sklenar, 1988).
short communications
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Figure 2
Stereoviews of the ellipticine–DNA complex. (a) The bis-intercalated
d(CGATCG)2 hexanucleotide forming an asymmetric unit. The drug and each
strand of the DNA are represented in different colours. Red spheres represent Co
atoms. (b) 2Fo " Fc electron-density map at the area of the intercalated ligand,
lo king into the minor groove. The map was contoured at the 1.0" level. (c)
Projection down the helix axis of a d(CpG)-d(GpC) dinucleotide with the
sandwiched ligand. (d) Superimposition of the structure from Jain et al. (1979) in
yellow an the equivalent part of the present structure in blue. (e) Three
asymmetric units illustrating the crystal packing of the ellipticine–d(CGATCG)2
structure. The drug is always coloured green and symmetry neighbours are in a
different colour. Water molecules (spheres) are included.
N
H
NHO 
 
 
 
Figure 1.6: 9-Hydroxyellipticine 6 
In 2005, Canals et al. published a crystal structure determination of ellipticine in complex with 
a six base-pair oligionucleotide – d(CGATCG)2, with 1.5 Å resolution.25 This showed 
ellipticine aligned with the major axis, parallel to the hydrogen bonds of the base pairs (Figure 
1.7). The d(CGATCG)2 hexanucleotide is intercalated by two ellipticine molecules, with the 
pyridine nitrogen facing the major groove in both cases. A preference for G-C base pairs is 
evident, since the AT-TA site is empty. Overall, there was good correlation with the earlier 
dinucleotide structure published by Jain et al.19 (Figure 1.7 – part c). In Canals crystal structure 
an unwinding angle of 14º with respect to standard B-DNA was observed for each 
intercalation site and both sites were separated by 6.9 Å (compared to 3.3 Å for normal base 
pairs). 
 
 
 
 
           (b) 
 
 
 
 
 
           (c) 
         (a) 
Figure 1.7: (a) The bis-intercalated d(CGATCG)2 hexanucleotide. (b) Projection down the helix axis of a 
d(CpG)-d(GpC) dinucleotide with the sandwiched ligand. (c) Superimposition of the structure from Jain et al. 
(1979) in yellow and the equivalent part of Canals’ structure in blue.25 
In recent years, various molecular modelling studies concerned with intercalation of ellipticine 
and its derivatives have been published.26–31 These were mainly concerned with comparing the 
usefulness of different force fields and the optimum modelling parameters for the ellipticine 
series, however, little new data on the binding mode has been reported.  
 
In summary, considerable research has been carried out in the area of ellipticine in er alation 
with DNA. Recent work by Canals et al. has established an intercalation model with ellipticine 
parallel to the axis of the base pairs with the pyridine nitrogen facing the major groove.25 
While this seems to be a definitive binding mode for ellipticine, derivatives of ellipticine may 
intercalate in different orientations or possibly not at all. 
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1.3.1.2 Topoisomerase II inhibition 
DNA topoisomerases are enzymes that regulate the three-dimensional topology of DNA. 
Identical loops of DNA with different numbers of twists are topoisomers, i.e. molecules with 
the same chemical formula but different topologies, interconversion of these topoisomers 
requires breaking of DNA strands.3 Topoisomerase I produces single strand breaks in DNA 
allowing the release of superhelical tension, while topoisomerase II produces double strand 
breaks, allowing separate strands of DNA to pass over each other and untangle. These 
processes are crucial for replication and transcription. 
 
Topoisomerase II is a homodimeric enzyme which requires ATP to function. In the initial 
strand cleavage step, tyrosine residues of both monomers attack a phosphodiester bond in 
either strand to give covalent 5' phosphotyrosyl linkages (Scheme 1.13). The religation step is 
simply the reverse reaction.  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.1: Transesterification reactions involved in topoisomerase II activity.3                                     
(Reaction of one monomer shown) 
The two breaks in the DNA strand are not directly opposite each other, but are separated by 
four base pairs, in this way a space is created through which another region of intact DNA can 
pass. Figure 1.832 shows a schematic of the catalytic cycle of topoisomerase II, with cleavage 
of the G-segment of DNA and the T-segment passing through the complex, followed by 
religation (see over). 
 
Levels of topoisomerase I and II are different in different cell types. A study by Holden et al. 
in 1990 measured topoisomerase II activity in normal and neoplastic tissues.33 The highest 
levels in normal tissues were found in the spleen and thymus. In neoplastic tissue, the highest 
levels were found in those that are clinically most aggressive and proliferative, such as breast 
carcinoma and lymphomas. These measurements serve to explain the selectivity exhibited by 
topoisomerase II inhibitors and validate topoisomerase II as a key target for cancer 
chemotherapy. 
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Figure 1.8: Catalytic cycle of topoisomerase II.32 Topo II binds to a segment of DNA (G-segment, red bar), 
ATP (yellow circle) binds to the N-terminal domains, promoting the capture of a second DNA duplex, the T-
segment (green bar) and dimerization of the ATPase domains (N-gate). Closure of the N-gate stimulates 
cleavage of G-segment DNA, coupled with opening of the DNA gate to allow passage of the T-segment 
through this double-stranded break. The G-segment is religated and the T-segment exits via the C-gate. 
 
In the 1960s and 70s it was recognised that intercalating drugs produced single and double 
strand breaks in DNA, however the mechanism of this process was unknown. In 1978, Ross 
et al.34 reported that DNA strand breaks produced by ellipticine were intimately associated 
with a protein, but it wasn’t until the early 1980s that a series of studies on doxorubicin and 
ellipticine identified the protein involved as topoisomerase II.35–38 
 
Later, Corbett and Osheroff proposed that topoisomerase II inhibitors fall into two 
mechanistic classes: (1) those that inhibit enzyme-mediated religation by stabilizing the 
cleavable complex and (2) those that increase the forward rate of enzyme-mediated DNA 
cleavage.39 The first class are also known as topo II poisons since they subvert the activity of 
topo II to produce permanent double strand breaks in DNA e.g. etoposide and doxorubicin 
(Figure 1.9). The second class are known as catalytic inhibitors as they act on other steps of 
the catalytic cycle e.g. aclarubicin and sobuzoxane.3 Interestingly, there is no correlation 
between the binding mode (intercalative or outside binding) of a drug and its mechanistic class 
(poison or inhibitor).39 
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Figure 1.9: Examples of Topoisomerase II poisons and inhibitors 
 
Ross and Bradley were the first researchers to associate ellipticine induced DNA strand breaks 
with topoisomerase II inhibition.40 Ellipticine was found to induce strand breaks in DNA 
from L1210 cells, in concentrations of 1.25 – 5.0 µg/mL and the authors to proposed the 
strand breaks were due to topoisomerase II activity. 
 
In 1984, Tewey et al. demonstrated that ellipticine 1 and 9-hydroxy-N-methylellipticinium 3 
produced reversible protein-linked DNA strand breaks in vitro.41 9-Hydroxy-N-
methylellipticinium 3 was found to be the more effective of the two compounds, and it was 
suggested that ellipticines exerted this action via stabilisation of the DNA-topo II cleavable 
complex. Charcosset et al. isolated a Chinese hamster lung cancer cell line resistant to 9-
hydroxyellipticine 6 and topoisomerase II inhibitors (amsacrine and etoposide).42 This cell line 
was found to exhibit 3.5-fold lower topo II activity than the parent cell line (DC-3F), 
suggesting that 9-hydroxyellipticine resistance was due to lower levels of topoisomerase II.  
 
Froelich-Ammon et al. published a major study of ellipticine-topoisomerase activity in 1995, 
identifying topoisomerase II as the primary cellular target of the drug.43 This was determined 
by employing yeast cells with a temperature sensitive strain of topo II (at 25 ºC enzyme 
activity is 100% and at 30 ºC activity decreased to 10%). At 25 ºC, 90% of the cell culture was 
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killed by a 200 µg dose of ellipticine, while at 30 ºC, no cell death was observed at any 
concentration of ellipticine used. 
 
In a second experiment, a 10 µg dose of ellipticine induced a 6-fold increase in topoisomerase 
II-mediated strand breakage, but the same concentration of ellipticine had no effect on the 
rate of religation. Thus, ellipticine may be considered to be a catalytic inhibitor of topo II as 
opposed to a topo II poison, i.e. ellipticine acts primarily by increasing the forward rate of 
cleavage of DNA.  
 
Fluorescence spectroscopy was then used to study interaction of ellipticine with DNA, topo II 
and the DNA-topo II complex. Three possible mechanisms for complex formation were 
identified: (1) the drug binds only to pre-formed DNA-topo II complex, (2) the drug becomes 
part of the ternary complex primarily though interactions with DNA, and (3) the drug 
becomes part of the complex though interactions with the enzyme. It was established that 
protonated ellipticine binds to DNA, whereas deprotonated ellipticine binds to topoisomerase 
II and is also the major species present in the ternary complex. Thus the enzyme determines 
the protonation state of ellipticine in the ternary complex. Finally the authors proposed a 
binding model (Figure 1.10) in which the topoisomerase II-ellipticine-DNA ternary complex 
(complex c) is formed via the prior association of the drug with either DNA (complex a) or 
the enzyme (complex b). Formation of the ternary complex results in increased levels of 
covalent topoisomerase II-DNA cleavage complex (d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.10: Model of ellipticine binding to DNA (G segment, red), topoisomerase II (purple arc) and the 
topoisomerase II-DNA complex (adapted from Froelich-Ammon, 1995).43 
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1.3.1.3 Bio-oxidation and adduct formation  
The bio-oxidation pathway was originally proposed by Auclair and Paoletti, who postulated 
that ellipticine could serve as a substrate for peroxidises in vivo.44 They employed a horse radish 
peroxidise (HRP) – hydrogen peroxide oxidizing system as a model of bio-oxidation and 
studied the ability of various ellipticines to undergo oxidation. Under these conditions, 
9-hydroxyellipticine 6 was oxidised to the quinone imine 7 (Scheme 1.2). The quinone imine 7 
was shown to be a strong electrophile, oxidizing NADH to NAD+. It is also highly susceptible 
to nucleophilic attack at the C-10 position, and bound irreversibly to bovine serum albumin.44  
 
 
 
 
 
 
           6              7 
Scheme 1.2 
The group continued their investigation by studying the bio-oxidation of 9-hydroxy-N-
methylellipticinium acetate 8 under the same conditions.45 The expected quinone imine 9 was 
formed with one equivalent of hydrogen peroxide, however in the presence of excess 
peroxide, further oxidation occurred to yield the o-quinone 10 (Scheme 1.3).  
 
 
 
 
 
  8     9         10 
Scheme 1.3 
In vitro testing of these products against murine leukaemia L1210 showed that the quinone 
imine 9 was highly cytotoxic, with an ID50 value of 0.05 µM, while the o-quinone 10 was much 
less active at 9.6 µM. The quinone imine 9 was subsequently shown to bind covalently to 
DNA, giving a DNA-ellipticinium adduct.46 The fluorescence properties of the adduct 
indicated binding at C-10 of the quinone imine with a primary amine of DNA. 
 
In the last decade, Stiborová et al. have extensively studied the bio-oxidation and adduct 
formation pathways of ellipticine in vitro and in vivo. The group began by investigating the 
potential of ellipticine to form DNA adducts after activation by cytochrome P450 (CYP).47 
Cytochrome P450 enzymes were chosen based on the observation that several tumour types 
specifically targeted by ellipticine (e.g. breast cancer and renal cell cancer) overexpress CYPs. 
Rat, rabbit and human microsomes, in the presence of NADPH, were effective in activating 
ellipticine towards forming DNA adducts. Two adducts were formed with calf thymus DNA, 
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one major and one minor. A 32P-postlabelling assay confirmed that the adducts were covalent 
in nature. The minor adduct was formed independently of enzymatic activation (no change 
was observed on increasing the CYP concentration), whereas the major adduct was formed on 
catalysis by CYP.  
 
The group then investigated adduct formation in intact cells, using V79 cells expressing CYP, 
and based on HPLC profiles, the same two adducts were formed.48 In an effort to identify the 
site of adduct formation on DNA, a variety of different polydeoxyribonucleotides were used 
in binding experiments with CYP and ellipticine.49 Only 32P-labelled adducts derived from 
deoxyguanosine were found, indicating that guanine is the site of adduct formation with the 
activated ellipticine species.  
 
The next step was to identify the metabolites formed by human cytochrome P450 enzymes.50 
This was accomplished by isolation and HPLC separation of ellipticine metabolites generated 
by hepatic microsomes from eight human donors. Five metabolites were assigned based on 
co-chromatography with synthetic standards, NMR experiments and mass spectrometry 
(Scheme 1.4). 13-Hydroxyellipticine and the ellipticine N-oxide were identified as the 
metabolites responsible for the two DNA adducts previously identified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.4: Metabolism of ellipticine by human cytochrome P450 enzymes.51 
The group turned their attention to the peroxidase-mediated oxidation of ellipticine and 
performed experiments with peroxidases (human myeloperoxidase, human and ovine 
cyclooxygenases, bovine lactoperoxidase and horseradish peroxidase).52 Two metabolites were 
isolated and identified, an ellipticine dimer and ellipticine N-oxide (Figure 1.11). Four DNA 
adducts were formed, two major and two minor. The two major adducts corresponded to 
those previously identified, derived from 13-hydroxyellipticine and ellipticine N-oxide. The 
same adducts were formed in leukaemia HL-60 and CCRF-CEM cells and a good correlation 
between cytotoxicity and the levels of DNA adducts was observed.53 In particular HL-60 is 
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IC50 value of 0.64 µM.  
 
 
 
 
 
 
 
 
 
Figure 1.11 
In 2007, Stiborová et al. published an investigation into the formation and persistence of DNA 
adducts in rats and found the highest levels of adducts in the liver (402 adducts/108 
nucleotides after 2 days and 3.6 adducts/108 nucleotides after 32 weeks), followed by the 
kidney, lung, spleen, heart and brain.54 Once again the two major adducts were those 
previously reported. During this study it was also found that ellipticine induced CYP1A1 and 
CYP1A2 activity in the liver, lungs and kidneys of rats.55 
 
In their recent work Kotrobova et al. found that cytochrome b5 alters the ratio of ellipticine 
metabolites formed by CYP1A1 and CYP1A2, favouring the formation of 12-
hydroxyellipticine and 13-hydroxyellipticine metabolites implicated in adduct formation.56 
 
The key on-going question in this area is whether adduct formation is responsible for the 
cytotoxicity of ellipticines. A recent publication by Stiborová et al. sought to evaluate the 
contribution of DNA adduct formation to cytotoxicity and found plausible correlation in six 
out of seven cancer cell lines tested.57 However, further work is required in this area in order 
to conclusively understand this mechanism and its overall contribution to ellipticine 
cytotoxicity. 
 
 
 Kinase Inhibition 1.3.2
In the last decade, ellipticine interactions with several enzymes have been studied, including 
inhibition of c-Kit kinase and AKT. 
 
1.3.2.1 c-Kit Kinase 
In 2005, ellipticine and its derivatives were shown to exhibit c-Kit kinase inhibition.58 c-Kit 
kinase is a type III receptor tyrosine kinase (RTK), a class of enzymes which regulate 
signalling pathways that control cell growth and proliferation. c-Kit plays a key role in mast 
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cell survival, differentiation, maturation and function.59 It is expressed by and critical for the 
development and growth of mast cells, melanocytes, hematopoetic stem cells and the 
interstitial cells of Cajal.60 Mutations in the gene encoding for c-Kit kinase are associated with 
some highly malignant cancers and therefore both wild-type and mutated c-Kit are viable drug 
targets in anticancer chemotherapy.61  
 
In general, protein kinases regulate the biological activity of other proteins by phosphorylating 
specific amino acids, with ATP as the source of phosphate.3 To date, over 500 protein kinases 
have been identified, the majority of which are tyrosine kinases, that is, kinases which 
phosphorylate the phenolic hydroxyl group of tyrosine (Figure 1.12). 
 
 
 
 
 
 
Figure 1.12: Phosphorylation by tyrosine kinases.3 
Many tyrosine kinases are cytoplasmic, while others traverse the cell membrane and are known 
as receptor tyrosine kinases (RTKs). c-Kit kinase is one such transmembrane receptor, and it’s 
extracellular ligand is stem cell factor (SCF, also known as steel factor and mast cell growth 
factor).62 The c-Kit structure consists of an extracellular ligand binding domain (comprised of 
five immunoglobulin-like domains), a transmembrane domain, an inhibitory juxtamembrane 
helix and a cytoplasmic kinase domain which functions as the enzymatic pocket for tyrosine 
phosphorylation.  
 
Structural studies have elucidated the basis for c-Kit activation, via SCF binding and 
dimerisation.62 Binding of stem cell factor (SCF) in the extracellular domain induces 
dimerisation and activation. This results in auto-phosphorylation of specific tyrosine residues 
in the intra-cellular region which serve as docking sites of signal transduction molecules.63  
 
 
1.3.2.2 Mutations in c-Kit 
The c-Kit oncogene may undergo several mutations which then code for mutated c-Kit 
kinase, such mutations are associated with several highly malignant cancers.64,65 Longley et al. 
proposed classification of activating mutations into two groups, enzymatic pocket mutations 
and regulatory mutations.62 The first group consists of mutations found only in the 
intracellular enzymatic pocket, while the second group affect other portions of the molecule 
which regulate kinase activity. Figure 1.1362 shows a schematic diagram of a c-Kit monomer 
with specific mutations indicated opposite the corresponding regions. 
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Figure 1.13: Mutations in c-Kit62 
Longley et al. predicted that c-Kit with regulatory type mutations would pose little problem to 
wild type c-Kit kinase inhibitors. This has been shown in the case of gastrointestinal stromal 
tumours (GIST), where up to 90% of patients exhibit c-Kit mutation in the juxtamembrane 
region and the wild type c-Kit inhibitor imatinib (STI571) 11 has been used as a successful 
treatment (Figure 1.14).66  
 
 
 
Figure 1.14: Imatinib 11 
In contrast to this, wild type c-Kit inhibitors are ineffective at inhibiting c-Kit kinase with 
enzymatic pocket mutations.67 The most common enzymatic pocket type mutation is the 
D816V point mutation (replacement of aspartic acid by valine at point 816). Residue 816 is 
thought to contribute to the structure of the activation loop by forming a hydrogen bond with 
N819. The D816V mutation disrupts this bond and thus destabilises the inactive 
conformation of the kinase domain. This results in a shift in the conformational equilibrium 
of c-Kit towards the active conformation, leading to ligand independent activation and auto-
phosphorylation of c-Kit.58 This explains the inactivity of imatinib against D816V mutated c-
Kit, as it has been shown to bind only to the inactive conformation.68 
 
The D816V mutation is associated with germ cell tumours, adult mastocytosis and a small 
proportion of atypical paediatric mastocytosis.69,70 Mastocytosis is a disease characterised by 
pathological accumulation and activation of mast cells in tissues such as skin, bone marrow, 
liver, spleen and lymph nodes.71 Adult onset mastocytosis usually displays bone marrow 
involvement at the time of diagnosis and follows a progressive course with poor prognosis.61 
The D816V mutation is detectable in over 70% of patients with systematic mastocytosis in 
bone marrow cells. Treatment is currently very limited and fails to produce remission in most 
patients.61 This has attracted significant interest in developing new c-Kit inhibitors which are 
active against the D816V mutation72 and resulted in the development of Dasatinib 12 (BMS-
354825), which was approved by the FDA in 2006.73 
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Figure 1.15: Dasatinib 12 
1.3.2.3 Ellipticine and c-Kit kinase inhibition 
In 2005, Vendome et al. reported that several ellipticine derivatives exhibited c-Kit kinase 
inhibition.58 A range of derivatives significantly inhibited both wild type and D816V mutated 
c-Kit kinase (Table 1.3), with Imatinib 11 as a reference compund. 
 
Compound 
IC50 
WT 
µM 
IC50 
D816V 
µM 
Compound 
IC50 
WT 
µM 
IC50 
D816V 
µM 
 
 
11 
0.1 10 
13 
2.3 1.9 
 
6 
0.4 0.4 
14c 
2.5 2.0 
 
3 
0.4 0.4 
15 
2.5 3.6 
 
16 
 
0.45 
 
0.3  
1 
>10 >10 
 
17 
0.8 0.6 
 
18 
>10 >10 
 
14f 
1.4 1.2    
Table 1.3: Inhibition of wild type and D816V mutated c-Kit kinase by ellipticine derivatives.58 
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mutant should be active against the wild-type c-Kit,
consistent with the results in Table 1.
Therefore, we used a crystal structure very similar
to the active conformation of wild-type c-Kit to search
for the ellipticine binding site on the mutant.
Ellipticine Binding Mode Determination. All of
the compounds listed in Table 1 were docked on our
model of the D816V c-Kit mutant. Because ellipticine
compounds have been shown to be ATP-competitive
inhibitors, we restricted our search to the catalytic site
area.
We can group the compounds into three groups
according to their binding mode. First, all of the active
compounds (2, 3, 4, and 5) docked very similarly in a
site that is made favorable by three conserved interac-
tions (Figure 5A,B): the-NH at position 2 is an H-bond
donor to the -OH of Thr 670, and the -OH at position
9 is an H-bond donor to the carboxylic of Glu 640 and
an H-bond acceptor from the ammonium group of Lys
623. Second, the docking of the inactive compounds (10
and 11) occurred at the same position but in a confor-
mation (the planar cycle core flipped) different from that
of the active compounds in which the three interactions
are clearly impossible (Figure 5C). Third, the weakly
active compounds (6, 7, 8, and 9) (Figure 5D) bound less
specifically at the same site, as we found several other
binding sites for each of these compounds. The long,
bulky substituent of these compounds at position 1
makes specific binding less favorable. The pyrrolic
nitrogen was not involved in the binding for some of
these sites. Also, the binding mode that we found for
compound 7 can explain its activity, which, despite
lacking an -OH at position 9, has an activity similar
to compounds 6 and 8. We found that the N7 interacts
with the backbone nitrogen atom of Cys 673, compen-
sating for the lack of 9-OH.
Figure 4. (A) In the crystal structure, STI-571 binds to the
characteristic inactive conformation of c-Kit (PDB code 1T46).27
(B) For comparison, the docked position of compound 2 in the
D816V c-Kit model.
Figure 5. (A) Detail of the docked position of the most active compounds (compound is 2 shown in gray, 3 is shown in green, and
4 is shown in orange). Conserved interactions are represented in dashed lines. (B) Map of the main interactions for compound 2.
(C) and (D) Docked position of the less-active compounds. The docked position of the active compound 2 is recalled (ball-and-
sticks representation, shown in gray) for comparison. (C) The cycles of compounds 10 (green) and 11 (magenta) are flipped in
comparison with the cycle of compound 2. These positions are less favorable because the “conserved interactions” previously
described (B) are no longer possible. (D) For compounds 6 (green), 7 (orange), 8, and 9, having the same tail in position 1, the
dockings revealed several possible binding sites. In particular, for some binding sites, the N6 is not involved in any interaction
(compound 9, not shown in the picture). It also shows how N7 can be involved in the binding of compound 7 (orange) and compensate
for the lack of the 9-OH.
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9-Hydroxyellipticine 6 and 9-hydroxy-N-methylellipticinium 3, were the most active of the 
series, with equal inhibition of wild type and D816V mutated c-Kit. These were closely 
followed by the N-alkylamino-9-hydroxyellipticinium 16 which showed a slight preference for 
D816V mutated c-Kit. Of the rest of the series, compounds which were unsubstituted at C-9 
were generally inactive and those with a C-9 methoxy group were only moderately active. Salt 
formation at the N-2 position did not seem to affect the c-Kit inhibitory activity, suggesting 
that the N-2 position is not directly involved in binding to c-Kit. Finally, addition of bulky 
alkylamino side chains at C-1 was significantly unfavourable for activity. 
 
The possibility of a covalent linkage between the ellipticine derivatives a d c-Kit kinase was 
investigated by incubating c-Kit with 9-hydroxy-N-methylellipticinium 3 and then washing the 
complex. The activity of the enzyme was not affected after washing, i dicating a non-covalent 
mode of binding.  
 
Molecular mechanics simulations were employed in order to identify possible binding sites, 
with docking sudies carried out using the GOLD program. It was fou  that all the active 
compounds docked similarly i  part of the ATP binding p cket, which is made fav urable by 
three hydrogen bonding interactions. The docked postion of the mos  active compunds is 
shown in Figure 1.16, along with hydrogen bonding interactions for 9-hydroxyellipticine 6.58 
 
 
 
 
 
 
 
 
 
Figure 1.16: (A) Detail of the docked position of the most active compounds (9-hydroxyellipticine 6 is shown 
in gray, 9-hydroxy-N-methylellipticinium 3 in green, and N-alkylamino-9-hydroxyellipticinium 16 in 
orange). Conserved interactions are represented by dashed lines. (B) Map of the main interactions for 
9-hydroxyellipticine 6.58 
 
 
1.3.2.4 AKT Inhibition 
In 2004, Jin et al. rep rted the inhibition of AKT by 9-methoxy-N-methyl lliptici ium acetate 
19.74 AKT is a serine/threonine kinase (i.e. it phosphorylates the hydroxyl group of serine and 
threonine residues of other proteins), which is activated in response to growth factors or 
cytokines by a mechanism involving PI3-K (phosphoinoside 3-kinase).75,76 It provides a 
survival signal that protects cells from apoptosis induced by various stresses. AKT is currently 
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known to phosphorylate Bad, glycogen synthase kinase-3 (GSK-3), forkhead transcription 
factor (FKHR) and caspase-9, and thus inactivate their apoptotic functions.74  
 
In 40 – 50% of endometrial cancers, AKT is overexpressed due to mutation of tumour 
suppressor PTEN (phosphatase and tensin homolog). 9-Methoxy-N-methylellipticinium 
acetate 19 (Figure 1.17) was tested against four endometrial cancer cell lines in a 12 µM or 
24 µM single dose. Inhibition of AKT kinase activity and apoptosis was observed in the two 
cell lines with high AKT levels (RL95-2 and Ishikawa cells) but not in the cell lines with 
normal AKT activity. Further investigation suggested that inhibition was at AKT level and not 
upstream kinases that phosphorylate AKT. 
 
 
 
 
 
Figure 1.17: 9-Methoxy-N-methylellipticinium acetate 19  
Later, Tang et al. found that the same compound (9-methoxy-N-methylellipticinium acetate 
19) inhibited AKT kinase activity in ovarian cancer cell lines with overactivation of AKT.77 In 
this case, 9-methoxy-N-methylellipticinium acetate 19 appeared to prevent phosphorylation of 
AKT at Ser473, so it is possible that inhibition of an upstream kinase such as PDK2 may be 
involved. Overall the compound selectively induced apoptosis in ovarian cancer cell lines with 
overactivation of AKT but had minimal effect on normal cells. 
 
In 2009, Fang et al. reported that growth of non-small cell lung cancer (NSCLC) epithelial cells 
A549 was inhibited by ellipticine 1.78 They proposed that ellipticine induced cytotoxicity by 
modulating the signalling pathways and subcellular redistribution of AKT and p53. 
 
 
 Other 1.3.3
1.3.3.1 Interaction with p53 tumour suppressor 
The protein p53 is a transcription factor that binds to specific DNA sequences thereby 
controlling the transcription of genetic information from DNA to mRNA.3 It is known as the 
‘guardian of the genome’ as it is the key transcription factor which orchestrates coordinated 
changes in proliferation and apoptosis. On activation, it increases transcription of genes 
involved in inhibition of DNA replication e.g. p21 and Gadd45, but has opposing effects on 
BAX and Bcl2 which help regulate apoptosis.1 In a general sense, p53 can help to promote the 
repair and survival of damaged cells, or it can promote the permanent removal of damaged 
cells though apoptosis. In the model of Vousden and Prives (Figure 1.18), p53 activity 
induced by low-stress elicits the protector responses that support cell survival and promote 
the repair of genotoxic damage.79 Sustained stress or irreparable damage, on the other hand, 
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induces the killer functions of p53 to activate cell death or senescence. Notably, the protector 
functions of p53 can contribute to tumor development if not properly regulated (red, dashed 
arrow).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.18: Dual mechanisms of p53 function (adapted from Vousden and Prives).79 
In more specific terms, damage to DNA activates p53, resulting in inhibition of proliferation 
via Gadd45, p21 and PCNA; along with activation of DNA repair pathways (Figure 1.19). 
Stimulation of BAX and inhibition of Bcl2  results in increased apoptosis.1 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19: Response of p53 to DNA damage.1 
In the last twenty years, the pivotal role of p53 in cancer has been elucidated. The gene TP53, 
encoding p53 protein, is mutated or deleted in approximately 55% of human cancers, mainly 
by point mutations in the core DNA binding domain.80,81 As a result of this, there has been 
increasing interest in molecules that interact with p53, especially mutated p53. In 1998, Shi et 
al.82 performed cluster analysis of 112 ellipticines from the NCI 60-cell line screen and found 
that the ellipticinium salts, but not the ellipticines, were more potent on average against p53 
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mutant cell lines over wild type p53 lines. This analysis opened up a new area of ellipticine 
research in the last decade. 
 
Sugikawa et al. found that 9-hydroxyellipticine 6 induced apoptosis in the G1 phase of the cell 
cycle of mutant p53 cells.83 They suggested that this activity may be via restoration of wild type 
p53 function. Mizumoto et al. then examined the impact of 9-hydroxyellipticine 6 on the 
cellular responses to various antineoplastic agents in pancreatic cancer cells. Exposure of 
mutant p53 expressing cells to 1 µM of 9-hydroxyellipticine resulted in restoration to wild type 
p53 activity without producing apoptosis. This pre-treatment with 9-hydroxyellipticine 
sensitised cells to treatment with cisplatin and mitomycin C, but not 5-fluorouracil, etoposide 
or vincristine. The effect was limited to cells expressing mutant p53. 
 
In 2003, Peng et al. definitively showed that ellipticine and several derivatives can activate the 
transcription function of p53, increasing the function of some mutant p53 types by 5-6 fold.84 
Ellipticine derivatives induced cell cycle arrest in wild type p53 cells, with accumulation at the 
G2/M phase. This activity was attributed to intercalation and topoisomerase II inhibition (i.e. 
activity independent of p53 activation), whereas in cells with mutant p53, treatment with 
ellipticine resulted in apoptosis. In mutant p53-transfected H1299 cells, ellipticine induced 
MDM2 and p21 expression indicating activation of p53 function, at an optimal dose of 8 µM. 
Since mutant p53 has an altered conformation that can be detected by immunoprecipitation, it 
was shown that treatment with ellipticine induced a shift of mutant p53 conformation towards 
that of wild type p53, thus restoring function. 
 
Kuo et al. studied the molecular mechanism of ellipticine activity in human breast MCF-7 
cancer cells and showed that induction of p53, Fas/Fas ligand death receptor activation and 
the mitochondrial proapoptotic pathway are all involved in ellipticine action on these cells.85 
An IC50 value of 1.52 µM was recorded, with cell cycle arrest at the G2/M phase. 
Upregulation of p53, KIPI/p27 was observed, along with increased expression of the Fas 
ligands, mFasL and sFasL. In the mitochondrial proapoptotic pathway, increased expression 
of BAX and decreased Bcl2 and Bcl-XL induced the release of cytochrome C from 
mitochondria to cytoplasm, which then activated caspase-9. 
 
The same group carried out a similar study on ellipticine action in hepatocellular carcinoma 
(HCC) cells.86 On treatment with ellipticine (IC50 = 4.1 µM), p53 levels increased in a dose 
dependent manner and reached maximum levels at 12 hours. Fas receptor and Fas ligand 
expression increased after 3 hours and the activity of caspase-8, a major downstream caspase 
of the Fas/Fas ligand system was increased after 6 hours. Increased levels of the Bcl2 family 
proteins involved in the proapoptotic mitochondrial pathway were also observed, along with 
decreased mitochondrial membrane potential, which resulted in release of cytochrome C to 
the cytoplasm. 
 
In 2008, Xu et al. developed a high-content screen for compounds which increase localisation 
of p53 to the nucleus of cytoplasm.87 Ellipticine was among several hits resulting from this 
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screen and was subjected to further testing. In HCT116 colon cancer cells expressing wild 
type p53, ellipticine was found to increase overall levels of p53 and induce localisation in the 
nucleus, resulting in increased p21 expression. This result was in contrast to previous work, 
which reported that ellipticine had no effect of cells expressing wild type p53.83,84 It was also 
shown that p53 localisation was unrelated to ellipticine action on DNA or topoisomerase II, 
since p53 localisation in the nucleus was observed within one hour, whereas DNA damage 
was not observed until 16 hours after treatment. 
 
Lu et al. identified the ellipticine derivative, 3-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-
b]carbazol-6-yl)propan-1-aminium chloride 20 as a potential lead compound for p53 activation 
and studied its effects on three cancer cell lines.88 HCT116, a wild type p53 line; SW620 with 
mutant p53 and HCT116 p53-/-, a p53 deficient cell line were treated with 20, with GI50 values 
between 0.5 and 1 µM. Induction of p53 activity was observed in all three cell lines, but was 
highest (7.5 fold activity) in HCT116 and much less in SW620 (1.5 fold). Two p53 target 
proteins, p21 and DR5 were also upregulated in all three cell lines. Another transcription 
factor p73, with similar function to p53, was also found to be critical in the anti-tumour 
effects of compound 20. 
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Figure 1.20: 3-(9-Methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-6-yl)propan-1-aminium chloride 
Recent studies have focused on combination treatments of ellipticine with exisitng well known 
anit-cancer agents. Huang et al. found that combined treatment of DLD1 cancer cells with 
5-fluorouracil and ellipticine resulted in increased cell death compared to treatment with either 
agent alone.89 Wang et al. recently reported that ellipticine alone did not alter p53 expression 
levels in mutant p53 Raji cells.90 However, in chemo-resistant mutant p53 Ramos cells, 
ellipticine treatment sensitised cells towards doxorubicine-induced apoptosis. 
 
 
1.3.3.2 Mitochondrial damage 
Ellipticine interactions with mitochondria have been briefly mentioned in section 1.3.3.1, Kuo 
et al. found that the proapoptotic mitochondrial pathway was involved in the cytotoxicity of 
ellipticine towards human breast MCF-7 cancer cells and hepatocellular carcinoma (HCC) 
cells.85,86 Schwaller et al. specifically investigated ellipticine induced uncoupling of 
mitochondrial oxidative phosphorylation.91 They found that ellipticine had a potent effect on 
mitochondria and proposed a cyclic efflux/reuptake mechanism for ellipticines: (i) 
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electrophoretical accumulation of the protonated form of ellipticine in the negatively charged 
mitochondrial matrix; (ii) deprotonation at the matrix interface; (iii) diffusion outwards; (iv) re-
protonation at the external surface. Thus, the protonatable ellipticines induced depolarisation 
of the mitochondrial inner membrane much more efficiently than ellipticinium cations (where 
no cyclic mechanism is possible). 
 
Tian et al. used the COMPARE algorithm to correlate high expression of CKS1B mRNA (a 
high-risk molecular marker in multiple myeloma) in the NCI 60-cell line panel with GI50 values 
and identified the 9-(N,N-dimethyl ethanamine)-oxyellipticine derivative 21 as a lead 
compound.92 
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Figure 1.21: 9-(N,N-dimethyl ethanamine)-oxyellipticine derivative 
Ellipticine derivative 21 was found to rapidy accumulate in mitochondria and immediately 
initiate loss of mitochondrial membrane potential, release of cytochrome C and formation of 
large vacuoles. Cells treated with 21 produced the lowest ATP levels of all the compounds 
tested, suggesting uncoupling of mitochondrial oxidative phosphorylation, which would thus 
block energy production in the cell. Although CKS1B gene expression was the initial seed of 
the investigation, gene expression profiling results showed no significant change in CKS1B 
expression.  
 
 
1.3.3.3 Induction of endoplasmic reticulum stress 
Hägg et al. investigated the activity of the 6-propanamine ellipticine derivative 22 (Figure 1.22) 
and found that it induced rapid apoptosis in MDA-MB-231 breast cancer cells.93 In particular, 
6-propanamine ellipticine was found to induce endoplasmic reticulum stress, as evidenced by 
increased expression of the endoplasmic reticulum chaperone GRP78, followed by release of 
cytochrome C from mitochondria and caspase cleavage of CK18. On the basis of this, the 
authors proposed that apoptotic signalling is triggered by endoplasmic reticulum stress, which 
contributes to the cytotoxicity of 6-propanamine ellipticine 22, but the extent of this 
contribution is uncertain. 
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Figure 1.22: 6-Propanamine ellipticine 
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 Summary 1.3.4
Since its discovery, several key mechanisms of action have been found to contribute to 
ellipticine anticancer activity. These include DNA intercalation and topoisomerase II 
inhibition, two closely related mechanisms which have been well established in the literature. 
More recent investigations have shown that ellipticines induce multifaceted biological 
responses, including interaction with kinases, p53 tumour supressor, mitochondria and 
endoplasmic reticulum. The relative contributions of these interactions are difficult to 
establish, and further research in the area is required, however it seems clear that the ellipticine 
family of compounds are truly multi-modal anticancer agents. 
 
 
1.4 Design of ellipticine anticancer agents 
 
While ellipticine and 9-hydroxyellipticine exhibit potent anticancer activity, properties such as 
low solubility and bioavailability have impeded their use in a clinical setting. To this end, a 
range of ellipticine derivatives, hybrids and conjugates have been synthesised and evaluated 
for potential improvement in cytotoxicity. 
 
 
 
 
 
 
Figure 1.23: Ellipticine numbering system and main areas of derivatisation. 
 
 Ellipticine derivatives 1.4.1
In 1976, Le Pecq et al. carried out a detailed study on the antitumour activity of 9-
hydroxyellipticine 6 against L1210 mouse leukaemia.94 This in vivo mouse study demonstrated 
the overall potency of 9-hydroxyellipticine against intra peritoneal (i.p.) implanted L1210 
leukaemia. When administered by i.p. injection, 9-hydroxyellipticine killed >99% of cells, 
however a levelling off in the antitumour activity – dose relationship was observed at higher 
doses, indicating that a small number of cells were resistant to the treatment. This was 
extensively investigated and concluded to lack of tumour penetration by the drug. 
 
An early lead compound in ellipticine chemotherapy was N-methyl-9-hydroxyellipticinium 
acetate 3, known as Celiptium® (Figure 1.24 below). This compound entered clinical trials in 
1977 but did not progress beyond phase II.95–97 Nevertheless, the Celiptium was highly active 
and had good solubility compared to ellipticine, characteristics which researchers aimed to 
incorporate into new ellipticine derivatives. 
Quaternarisation to give 
ellipticinium salts 
Olivacine analogues 
Generally OH or OMe, 
but also some longer 
chain ethers 
N-6 alkylation 
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Auclair et al. prepared 2-(diethylamino-2-ethyl)-9-hydroxyellipticinium chloride (Datelliptium) 
23 and compared its activity with N-methyl-9-hydroxyellipticinium acetate 3 (Figure 1.24).98 
Both drugs were found to have similar DNA binding constants, with Kapp of 1.2 × 10
6 M-1 for 
N-methyl-9-hydroxyellipticinium acetate 3 and 1.04 × 106 M-1 for 2-(diethylamino-2-ethyl)-9-
hydroxyellipticinium chloride 23. However, there was a significant difference in the unwinding 
angles – 21.6º and 10.0º for 3 and 23 respectively. Both compounds were tested against L1210 
cells and 23 was found to be more cytotoxic, with ID50 = 0.076 µM compared to 3 (ID50 = 
0.134 µM). This superiority in cytotoxicity was seen across a range of cancer cell lines 
including P388 leukaemia, B16 melanoma, M5076 reticulosarcoma and colon 38 
adenocarcinoma. The authors proposed that the increased cytotoxicity of 2-(diethylamino-2-
ethyl)-9-hydroxyellipticinium chloride 23 may be due to an increase in diffusion across the cell 
membrane and more favourable bio-distribution compared to N-methyl-9-
hydroxyellipticinium acetate 3. 
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Figure 1.24: Celiptium 3 and Datelliptium 23 
Bisagni et al. prepared analogous 1-aminoellipticines 14 in 1979 (synthesis in chapter 2, section 
2.6.1, also used in c-Kit kinase inhibition testing, section 1.3.2.3).99 In later publications, the 
biological activity of these compounds was reported along with 7-aza and 9-azaellipticine 
analogues.100,101 The two most active compounds from the entire series were 1-[3-
(diethylamino) propylamino]ellipticines 14c and 14f. These derivatives had good DNA binding 
constants and excellent ID50 values (Figure 1.25 and Table 1.4). On the basis of this, a range 
of different 1-aminoellipticines was prepared, some of these displayed similar cytotoxicities to 
14c and 14f (e.g. the N-6 methylated analogues), however no further dramatic improvement 
was seen.101 
 
 
 R1 
Kapp  
(× 10-7 M-1) 
ID50  
(µM) 
14c CH3 3.15 0.3 
14f H 2.0 0.03 
 
Figure 1.25 and Table 1.4: DNA binding constants and ID50 values for 1-[3-(diethylamino) 
propylamino]ellipticines 14c and 14f 99 
NCI screening of a 9-methoxy analogue of Celiptium, N-methyl-9-methoxyellipticinium 
iodide 24 showed a remarkable and unexpected selectivity towards CNS cancer cell lines 
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(Figure 1.26). This result was particularly surprising given that Celiptium itself displayed no 
such selectivity. Acton et al. from the NCI later published screening results of a large panel of 
ellipticinium salts which were analysed for CNS cancer cell line selectivity (Table 1.5).102 It was 
proposed that C-9 substitution was key in the CNS selectivity of ellipticinium salts, however 
the C-9 unsubstituted salts (Table 1.5, entries 4 & 5) displayed equal selectivity to N-methyl-9-
methoxyellipticinium iodide 24 (entry 1). In addition, moderate selectivity was seen with 9-
methyl and 9-chloro ellipticinium salts (entries 6 & 7). Only the 9-hydroxyellipticinium salts 
showed no selectivity (entries 2, 8, & 9). The counter ion had little effect on specificity (entries 
1, 3, 4, & 5). Selectivity was lost or considerably diminished by quaternization with bulky 
groups or alkylation of the indole nitrogen with a bulkier group than methyl (results not 
shown). Also, the parent ellipticine compounds (R1=H, OMe, OH, Me, Cl) showed no 
specificity for CNS cell lines. 
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Figure 1.26: N-Methyl-9-methoxyellipticinium iodide 24 and general structure of ellipticinium salts. 
Entry R1 R2 X 
TGI (µM) 
Full panel (A) 
TGI (µM) 
CNS panel (B) 
Ratio  
A/B 
1 OMe Me I 11 1.1 9.8 
2 OH Me OAc 78 58 1.3 
3 OMe Me OAc 18 2.1 8.7 
4 H Me I 12 1.4 8.9 
5 H Me OSO2Me 11 1.0 11 
6 Me Me OAc 21 6.9 3.0 
7 Cl Me OAc 22 4.7 4.8 
8 OH CH2CH2NEt2 Cl 34 16 1.7 
9 OH CH2CH2NC6H10 OAc 34 20 1.7 
TGI: Total Growth Inhibition 
Table 1.5: CNS selectivity of ellipticinium salts102 
In the same year, Anderson et al. synthesised a panel of 9-substituted N-methylellipticinium 
salts and carried out the same NCI analysis as Acton et al. (Table 1.6).103 In general, a decrease 
in selectivity for CNS cell lines was observed with increasing size of the C-9 substituent. 
Exceptions to this are the trifluoroethyl ether compounds (entries 6 & 7) which show minimal 
growth inhibition overall but moderate inhibition of CNS cell lines. Once again the parent 9-
substituted ellipticines showed no specificity in growth inhibition or cytotoxicity. The only 
difference from the study by Acton et al. is the selectivity of 9-methoxy-N-methylellipticinium 
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acetate, which displayed much higher selectivity in Anderson’s study despite using the same 
cell lines for measurement (entry 1, Table 1.6 versus entry 3, Table 1.5).  
 
Entry R1 R2 X 
TGI (µM) 
Full panel (A) 
TGI (µM) 
CNS panel (B) 
Ratio  
A/B 
1 OMe Me OAc 21.4 0.63 33.9 
2 OCH2CH3 Me I 16.6 1.74 9.5 
3 OCH2CH3 Me OAc 25.7 3.63 7.08 
4 OCH(CH3)2 Me I 17.8 2.63 6.5 
5 OCH(CH3)2 Me OAc 25.8 12.4 2.1 
6 OCH2CF3 Me I 29.5 3.24 9.11 
7 OCH2CF3 Me OAc >72 5.25 13.7 
8 OPh Me I 37.6 18.2 2.1 
9 OPh Me OAc 36.6 11.9 3.1 
Table 1.6: CNS Selectivity of 9-substituted ellipticinium salts103 
Shortly after this, Vistica et al. published a specific investigation into the CNS selectivity of N-
methyl-9-methoxyellipticinium acetate (entry 1, Table 1.6) and found that its selective 
cytotoxicity was due in part to its preferential transport and accumulation in sensitive cell 
lines.104 
 
The evidence of CNS selectivity of ellipticinium salts prompted further investigation in this 
area. Jurayj et al. proposed that while ellipticinium salts may have high selectivity for CNS 
cancers in vitro, in vivo the ability of a charged ion to cross the blood-brain barrier (BBB) or 
enter the blood-cerebrospinal fluid (BCF) was relatively low.105 In an effort to overcome this 
Jurayj et al. prepared the neutral 2-alkyl-1,2-dihydroellipticines 25 (Figure 1.27), which would 
theoretically cross the blood-brain barrier and then undergo oxidation back to the 
corresponding ellipticinium salt. The ellipticinium salts were prepared and then reduced to the 
1,2-dihydroellipticines 25 (preparation in chapter 2, section 2.6.2). 
 
 
 
 
 
Figure 1.27: 1,2-Dihydroellipticines 25 
A panel of 2-alkyl-1,2-dihydroellipticines was prepared, unfortunately some of these were 
unstable in solution and converted back to the ellipticines over a short time. Those that were 
stable showed little growth inhibition or cytotoxicity in the NCI 60 cell line screen. 
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Most studies of ellipticine derivatives have sought to determine the cytotoxicity of derivatives 
towards specific cancer cell lines, however Fossé et al. specifically studied topoisomerase II 
mediated DNA cleavage by a range of ellipticine derivatives, providing an interesting insight 
into the structure-activity relationship for topo II inhibition.106 The relative frequency of 
cleavage of a 32P labelled pBr322 DNA fragment in the presence of calf thymus 
topoisomerase II and ellipticine derivatives was studied using agarose gel electrophoresis 
(Table 1.7). Of the ellipticines tested (entries 1 – 4), 9-hydroxyellipticine and 9-aminoellipticine 
were most active (entries 2 & 4). The N-methylellipticiniums generally showed higher activity 
than the ellipticines (entries 5 – 10), with consistently superior activity for the 9-hydroxy 
derivatives. The N-2-diethylaminoethyl chain conferred slightly reduced activity relative to the 
N-methyl salts (entries 11& 12 versus 5 & 6). In a surprising result, replacement of the C-5 
methyl group with an ethyl group significantly increased the cleavage frequency and this was 
the most potent topoisomerase II inhibitor of the series. 
 
 
 
 
 
 
Entry R1 R2 R3 R4 R5 
Conc. 
(µM) 
Relative 
Frequency* 
1 H - H H Me 4 1.6 
2 OH - H H Me 4 4.0 
3 OCH3 - H H Me 4 0.8 
4 NH2 - H H Me 4 2.4 
5 H Me H H Me 2 1.9 
6 OH Me H H Me 2 4.7 
7 H Me Me H Me 2 1.3 
8 OH Me Me H Me 2 6.2 
9 H Me H Me Me 1 1.8 
10 OH Me H Me Me 1 3.3 
11 H CH2CH2NEt2 H H Me 2 1.6 
12 OH CH2CH2NEt2 H H Me 2 3.6 
13 OH Me H H Et 2 8.2 
*Cumulative frequencies of cleavage pBR322 DNA relative to frequency of cleavage in the absence of 
drug. 
Table 1.7: Topoisomerase II inhibition of ellipticine derivatives106 
Honda et al. prepared N-glycosides of ellipticine in order to improve water solubility and 
selectivity towards tumour cells (see section 2.6.2 for synthesis).107,108 An extensive panel of 
ellipticine glycosides was prepared and tested against intra peritoneal (i.p.) implanted L1210 
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leukaemia in mice with i.p. administration over 5 days. Twenty six of the forty nine glycosides 
tested were curative, i.e. the mice tested survived for 80 days or longer. Of these 26 
compounds, 5 were selected for further testing against a range of cancer cell lines and two 
highly active compounds emerged, the L-arabinopyranoside 26 and D-xylofuranoside 27 
(Figure 1.28). 
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Figure 1.28: N-2-Ellipticine glycosides 
L-Arabinopyranoside 26 was curative against L1210 leukaemia in 2 of 6 mice, when 
administered intravenously for five days, with ILS% (increase in mean life span) of 344%. 
With P388 leukaemia, both L-arabinopyranoside 26 and D-xylofuranoside 27 were curative 
(2/6 and 2/6, ILS% = 394 and 417 respectively). Both compounds were much more active 
than ellipticine and celiptium, and in comparison with doxorubicin, the glycosides had better 
activity in L1210, P388 and colon 38 cell lines.  
 
Grummitt et al. investigated the introduction of a sugar moiety at C-9 of the two most active 
N-2 ellipticinium salts, 9-hydroxy-N-methylellipticinium acetate 8 and N-2-L-arabinose-9-
hydroxyellipticinium bromide 26.109 They postulated that such compounds could act as DNA 
threading agents, with intercalation via the ellipticine core, and the N-2 and C-9 substituents 
acting as major and minor groove binders. The ellipticine O-glycoside 28 and bis(glycoside) 29 
were prepared in low yields due to difficulties with purification (Figure 1.29). Interaction of 
these derivatives with calf thymus DNA was studied using flow linear dichroism spectroscopy. 
UV and LD spectra indicated that the derivatives 28 and 29 intercalate with DNA, and in the 
case of bis(glycoside) 29, this would only be possible if the molecule threads through the DNA 
with a sugar moiety in the major and minor grooves. No other biological data was reported 
for these compounds, presumably due to the minute quantities obtained from the synthesis. 
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Figure 1.29 
 
 Hybrids and Conjugates 1.4.2
In recent decades, a variety of ellipticine hybrids and conjugates have been prepared, opening 
up new avenues for improvement of anticancer activity. Such molecules have been designed 
with various aims e.g. increasing overall cytotoxicity, targeted delivery of ellipticine to cancer 
cells, or improving solubility and bioavailabity of the drug. In this section a hybrid is defined 
as a compound made up of chemical molecules with different biological properties e.g. an 
intercalator and a minor groove binder. When one of the elements in a hybrid is a biomolecule 
e.g. a protein or a nucleic acid, it is referred to as a conjugate. 
 
In 1991, Ding et al. prepared a panel of water soluble cationic metalloporphyrin-ellipticine 
hybrids based on mimicking the effects of the highly successful DNA cleaving agent 
bleomycin.110 The porphyrins had either one or two ellipticine molecules attached via a range 
of different side chains. The metals were also varied to include manganese, iron and zinc. 
Overall, the manganese derivatives were most active, with moderate activity for iron and 
complete inactivity with zinc. The most active hybrid contained a pentyl carboxamide linker 
with manganese chelated to the porphyrin (Figure 1.30). This compound had a high affinity 
for DNA (Kapp 2.0 × 10
8 M-1) and an IC50 value of 0.8 µM against murine leukaemia L1210 
cells. 
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Figure 1.30: Metalloporphyrin-Ellipticine hybrid 
Bailly et al. designed a distamycin-ellipticine hybrid as a bidentate DNA binding ligand, 
combining the powerful minor groove binding properties of distamycin and the intercalation 
ability of ellipticine.111 The first generation hybrid (Figure 1.31, R=CHO) was relatively 
unsuccessful, with lower affinity for DNA than either ellipticine or distamycin alone. The 
authors concluded that some mutual interference was occurring and carried out molecular 
modelling studies, which indicated that an extra positive charge on the distamycin moiety 
could overcome the problem.112 This was achieved by adding a basic side chain to the 
molecule (R=COCH2CH2NH3
+) to give a biscationic hybrid which was tested using circular 
and linear dichroism.  
 
 
 
 
 
 
 
 
 
 
  R=CHO, 
 
Figure 1.31: Distamycin-ellipticine hybrid 
This second generation compound was found to be selective for AT rich DNA sequences (in 
correlation with the parent distamycin moiety) and engaged in bidentate binding to AT 
sequences but not to GC sequences. In DNase I footprinting, the concentrations required to 
detect a clear footprint at AT sites with the 2nd generation hybrid were 4 to 10-fold lower than 
those required to produce comparable DNase I footprints with distamycin alone.  
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Routier et al. prepared the ellipticine-salen copper hybrid 30 and found that the ellipticine 
intercalation geometry was preserved and the salen copper complex allowed cleavage of DNA 
via oxygen radicals (Figure 1.32).113 Incubation of supercoiled plasmid DNA with 20 µM of 
the hybrid for 2 hours resulted in complete conversion to nicked form II DNA, whereas 
under the same conditions the salen copper moiety alone only converted ~50% to form II.  
 
 
 
 
 
 
 
Figure 1.32: Ellipticine-Salen Copper hybrid 30 
The first ellipticine bioconjugates were prepared by Devraj et al. in 1996.114 Three ellipticine-
estradiol conjugates were prepared in order to target the cytotoxicity of ellipticine to estrogen-
receptor positive cells (synthesis described in chapter 2, section 2.6). The molecules were 
linked via a 1,6-hexane diamide chain from the 17α position of estradiol to C-9, N-2 and N-6 
of ellipticine (Figure 1.32). The conjugates were tested for their abilities to bind to estrogen 
receptors, topoisomerase II inhibition and cytotoxicities against various cancer cell lines. The 
N-2 dihydroellipticine conjugate 31 showed moderate inhibition of topo II (IC50 24.1 µM) and 
was also cytotoxic (GI50 1 – 10 µM), whereas the C-9 and N-6 conjugates were inactive. 
Disappointingly, none of the three compounds displayed any selectivity for estrogen-receptor 
positive cells, and displayed weak binding affinities compared to estradiol. 
 
 
 
 
 
     N-2 conjugate 31 
 
 
 
 
C-9 conjugate 32 
 
 
 
 
 
     N-6 conjugate 33 
Figure 1.33: Ellipticine-estradiol conjugates 
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In 1998, Czerwinski et al. synthesised an ellipticine-heptagastrin conjugate, with the aim of 
targeting the cytotoxic action of ellipticine towards specific cancers.115 Heptagastrin is the C-
terminal heptapeptide of gastrin, the cell surface receptors of which are overexpressed in 
several gastrointestinal cancers. The resulting conjugate showed remarkable selectivity for 
gastrin receptor positive cells, with toxicities in the nanomolar range but was much less toxic 
to receptor negative cells. In fact, the ellipticine-heptagastrin conjugate bound to the gastrin 
receptors at levels close to the natural hormone (KD=1 nM). Ellipticine alone showed equal 
cytotoxicity to receptor positive and negative cell lines, and was comparable with that of the 
conjugate in the receptor positive cells in vitro. However, in vivo experiments showed that the 
conjugate was concentrated in cytotoxic concentrations in receptor positive cells, unlike free 
ellipticine, which failed to affect tumours at an equimolar dose. 
 
 
 
 
 
 
 
 
 
 
Figure 1.34: Ellipticine-Heptagastrin conjugate 
Moody et al. later utilised the same synthetic method to prepare ellipticine – VIP conjugates, 
where VIP is vasoactive intestinal peptide, a 28 amino acid peptide with receptor 
overexpression in breast cancer cell lines.116,117 Two ellipticine – VIP conjugates were found to 
inhibit VIP binding to MCF-7 breast cancer cells with IC50 values of 0.2 and 1 µM. A 1 µM 
dose of either of the conjugates resulted in decreased MCF-7 colony formation and decreased 
cell viability. Similar results were found with the lung cancer cell line H1299, with identical 
IC50 values of 0.2 and 1 µM for inhibition of VIP binding. 
 
In a recent publication, Sedlacek et al. reported preliminary work on a polymer-conjugated 
ellipticine auger electron emitter.118 Auger electron emitters are radionuclides such as 111In, 125I 
and 99mTc, which emit low energy ionizing radiation called Auger electrons. This radiation is 
biologically potent within a very short range in living tissue and thus requires targeting and 
delivery to the cell nucleus of tumour tissue. The polymer-conjugated ellipticine derivatives 
were designed to target tumour tissue in three ways: first, based on the polymer used and the 
EPR (enhanced permeation and retention) effect of solid tumours, the derivative should 
preferentially accumulate in tumour cells, next, pH controlled release of the radiolabelled 
ellipticine into the cell, and thirdly, delivery of the auger electron emitter to the nucleus via 
ellipticine intercalation with DNA. Results showed that the 9-125iodoellipticinium polymer was 
stable at pH 7.4 and released the free 9-125iodoellipticinium at pH 5 (solid tumours are 
generally acidic). The drug was found to accumulate in cell nuclei using confocal microscopy, 
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and intercalate with DNA (ethidium displacement assay). In addition to this the 
antiproliferative properties of the ellipticine derivative were retained, with IC50 values of 0.27 – 
8.8 µM against Raji, EL-4 and 4T1 cell lines. Disappointingly, the Auger electron effect was 
not achieved in this model, and work is on-going to improve the specific radioactivity of the 
ellipticine derivative. 
 
 
 
 
 
 
Figure 1.35: Polymer-conjugated Ellipticine auger electron emitter 
 
A broad range of ellipticine hybrids and conjugates have been prepared over the last twenty 
years, and while none of these have yet progressed to clinical trials, it seems that this area is 
key to the future development of chemotherapeutic ellipticine derivatives. 
 
 
1.5 Clinical use of ellipticine derivatives 
 
An early clinical trial of 9-hydroxyellipticine 6 was terminated due to solubility problems 
(Figure 1.36), however, in 1994 it was used against metastatic breast cancer in combination 
with etoposide, methotrexate and chlorambucil, producing 48% partial response (PR) and 
1.8% complete response (CR). 95, 119 
 
 
 
 
 
 
      9-Hydroxyellipticine 6         Celiptium® 8          Datelliptium 23 
Figure 1.36: Ellipticine derivatives used in clinical trials 
Clinical trials of 9-hydroxy-N-methylellipticinium acetate (Celiptium®) 8 began in 1977 and 
no favourable therapeutic response was observed in patients with advanced stages of gastric 
adenocarcinoma, lung carcinoma, metastatic soft tissue carcinoma, lymphoma or ovarian 
cancer. When administered to patients suffering from advanced metastatic breast cancer 
(refractory to all other treatment), 9-hydroxy-N-methylellipticinium acetate 8 induced 
objective remissions in 25% of patients, lasting up to 18 months.95 The dosage was 80 – 
100 mg/m2/week, via 1 hour i.v. infusion, for 4 weeks. The treatment was particularly 
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effective in patients with oesteolytic breast cancer metastasis. 9-Hydroxy-N-
methylellipticinium acetate 8 also gave 1 CR, 2 PR and 7 stabilisations out of 22 metastatic 
renal cancers.119 In another phase II study of 9-hydroxy-N-methylellipticinium acetate 8 
(100 mg/m2/week) in advanced breast cancer, an objective response rate (CR & PR) of 19% 
was observed out of 79 patients (30% in soft tissue metastases).96  
 
The clinical success of Celiptium® prompted extensive studies into the synthesis of 
ellipticinium analogues and several of these were brought forward for clinical trials. In 1992 
2-(diethylamino-2-ethyl)-9-hydroxyellipticinium chloride (Datelliptium) 23 was found to be 
active in previously treated metastatic breast cancer and devoid of the toxicities reported with 
9-hydroxy-N-methylellipticinium acetate 8. Dosage was 150 mg/m2/day i.v. for 5 days, every 
3 weeks, and the responses were 1 CR, 4 PR in 30 patients.119 The toxicity of datelliptium was 
mainly hepatic, and it induced rare and mild leukopenia and severe fatigue.  
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3.1 Overview 
 
As outlined in the introductory chapters, the natural product ellipticine 1 has been the source 
of a vast body of research in anticancer chemotherapy. Various derivatives of ellipticine have 
been the subject of clinical trials, but have unfortunately not progressed past phase II.1–3 Most 
derivatisation work has focused on the A-ring of ellipticine, particularly C-9 substitution e.g. 
9-hydroxyellipticine 6, and D-ring quaternary salt formation at N-2 e.g. 9-hydroxy-N-
methylellipticinium acetate 8 (Figure 3.1). These modifications resulted in increased anticancer 
activity and improved water solubility, as shown by the CLogP values below. 
 
 
 
 
 
  Ellipticine 1     9-Hydroxyellipticine 6   Celiptium® 8 
  CLogP: 4.37            CLogP: 3.70   CLogP: −1.06 
Figure 3.1 
Previous work within this research group focused on derivatisation of N-6, C-9 and N-2 of 
ellipticine.4 In particular, a large panel of novel ellipticinium salts was prepared, introducing a 
range of functionality in the salt side chain and also varying the side chain length. Several of 
these derivatives were found to exhibit strong inhibition of topoisomerase II activity and good 
overall cytotoxicity profiles. 
 
Looking at the body of research overall, it is clear to see that substitution at the methyl groups 
of ellipticine (C-5 and C-11) has not been extensively studied, nor have the ellipticine 
analogues, isoellipticine and deazaellipticine been thoroughly investigated. 
 
In addition to this, molecular modelling work carried out in collaboration with the Tyndall 
National Institute at the outset of this project focused on the inhibition of c-Kit kinase by 
ellipticine derivatives and the binding mode of ellipticine derivatives in the c-Kit active site 
(see appendices for full publication).5 Extensive molecular dynamics simulations of five 
different binding modes for 9-hydroxyellipticine 6 suggested a different binding mode to that 
proposed by Vendome et al. in 2005 (see Ch 1, section 1.3.2.3 for detail).6 In this new binding 
mode 9-hydroxyellipticine 6 was protonated at N-2, and based on pKa calculations, this seems 
likely to be the case in vivo. The key hydrogen bonding interactions are C(9)OH – Glu671 and 
N(2)H – Glu640, with the C-11 methyl group facing the protein backbone and the C-5 methyl 
group exposed to solvent (Figure 3.2). 
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Figure 3.2: Proposed binding mode of protonated 9-Hydroxyellipticine 6 in the c-Kit kinase active site, 
determined from Molecular Dynamics simulations.5 
In order to obtain definitive conformation of the binding mode of ellipticine derivatives in the 
c-Kit active site, synthesis of several ellipticine derivatives was required which would 
subsequently be studied for their c-Kit kinase inhibitory activity. Key derivatives required for 
testing included a range of C-11 and C-5 derivatives to probe the space and orientation within 
the active site, along with ellipticine analogues to assess the contribution of the pyridine 
nitrogen to the overall binding affinity. 
 
 
 Design of targets 3.1.1
In this work we seek to explore new molecular space around the ellipticine pharmacophore by 
undertaking the synthesis of a range of novel 5- and 11-substituted ellipticines (while 
maintaining the biologically important C-9 substituents). In particular, we were interested in 
the introduction of carbonyl and amide functionality at the C-5 and C-11 positions as new 
hydrogen bonding motifs in the ellipticine series (Figure 3.3). Amide formation would also 
allow for direct modulation of the substituent size depending on the amine used. 
 
 
 
 
 
 
Figure 3.3: Ellipticine derivatives targeted for synthesis and biological evaluation 
It was envisaged that successful derivatisation reactions in the ellipticine series would be 
applied to the preparation of novel isoellipticine and deazaellipticine derivatives (Figure 3.4), 
as models to probe the role and importance of the pyridine nitrogen. In addition to this, due 
to the interesting biological activity exhibited by novel ellipticinium salts previously prepared 
in the group, the synthesis of an analogous panel of isoellipticinium salts was also proposed. 
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Figure 3.4: Isoellipticine and Deazaellipticine derivatives targeted for synthesis 
 
3.2 Synthesis of Ellipticine Derivatives and Analogues 
 
After reviewing the synthetic routes towards ellipticine in the literature, Sauliner and Gribble’s 
highly versatile synthesis was selected (see Ch 2, section 2.3.2 for detail).7 The attraction in the 
route lay in the C-2 coupling reaction between an indole and a pyridine anhydride, which may 
be varied in order to prepare deazaellipticine and isoellipticine. In addition to this, the 
ketolactam indolo[1,2-b][2,7]naphthyridine-5,12-dione 89 has been shown to readily react with 
a range of alkyllithium reagents in a regioselective and sequential manner to give 5- and 11-
substituted ellipticines. 
 
 
 
 
 
 
Figure 3.5: Indolo[1,2-b][2,7]naphthyridine-5,12-dione 89 
In this work we proposed to expand the utility of the ketolactam 89 by investigating its 
reaction with alkenyllithium reagents in order to introduce C-5 and C-11 functionality. 
Another key aim was to investigate the reaction of indolo[1,2-b][2,7]naphthyridine-5,12-dione 
89 with Grignard reagents, specifically vinylmagnesium bromide. If successful, replacement of 
alkyllithiums with Grignard reagents in this route would significantly increase its 
attractiveness, with milder conditions and a simpler procedure.  
 
Successful derivatisation reactions in the ellipticine series would be applied to the preparation 
of novel isoellipticine and deazaellipticine derivatives.  
 
3.3 Evaluation of Biological Activity 
 
It was envisaged that evaluation of the anticancer activity of a range of novel ellipticines, 
isoellipticines and deazaellipticines would be achieved via several methods. These would 
include determination of specific anti-cancer properties such as inhibition of topoisomerase II 
activity (using a topoisomerase II decatenation assay), along with c-Kit kinase inhibition – as 
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part of a study to investigate the binding mode of ellipticine derivatives in the c-Kit active site 
and inhibition of other kinases (e.g. AKT). 
 
Together with these specific measurements, an overall measure of the cytotoxicity of novel 
ellipticine derivatives and analogues was envisaged by submission to the NCI 60-cell line 
screen. This service is provided by the Developmental Therapeutics Program (DTP) at the US 
National Cancer Institute and involves submission of novel compounds for evaluation of 
activity against 60 different human tumour cell lines, representing leukaemia, melanoma and 
cancers of the lung, colon, brain, ovary, breast, prostate, and kidney. This provides a highly 
useful overall picture of the cytotoxic activity of a compound and also highlights any 
specificity of the drug for certain cancer cell lines. 
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